Long-term efficacy and safety of eculizumab in Japanese patients with PNH: AEGIS trial

International Journal of Hematology

Volumn 98, Issue 4, 2013, Pages 406-416

  Kanakura, Yuzuru ^a   Ohyashiki, Kazuma ^b   Shichishima, Tsutomu ^c   Okamoto, Shinichiro ^d   Ando, Kiyoshi ^e   Ninomiya, Haruhiko ^f   Kawaguchi, Tatsuya ^g   Nakao, Shinji ^h   Nakakuma, Hideki ⁱ   Nishimura, Jun Ichi ^j   Kinoshita, Taroh ^k   Bedrosian, Camille L ^l   Ozawa, Keiya ^m   Omine, Mitsuhiro ⁿ  

^a OSAKA UNIVERSITY HOSPITAL   (Japan)

^b TOKYO MEDICAL UNIVERSITY   (Japan)

^c FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

^d KEIO UNIVERSITY HOSPITAL   (Japan)

^e TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f UNIVERSITY OF TSUKUBA   (Japan)

^g KUMAMOTO UNIV SCHOOL OF MEDICINE   (Japan)

^h KANAZAWA UNIVERSITY HOSPITAL   (Japan)

ⁱ WAKAYAMA MEDICAL UNIVERSITY   (Japan)

^j OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^k OSAKA UNIVERSITY   (Japan)

^l ALEXION PHARMACEUTICALS   (United States)

^m JICHI MEDICAL UNIVERSITY   (Japan)

ⁿ SHOWA UNIVERSITY FUJIGAOKA HOSPITAL   (Japan)

more..

Author keywords

Complement inactivating agents; Eculizumab; Hematopoietic stem cell; Hemolysis; Paroxysmal nocturnal hemoglobinuria

Indexed keywords

ECULIZUMAB;

ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; ANEMIA; ARTICLE; BONE MARROW DEPRESSION; BRONCHITIS; CELLULITIS; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; EPISTAXIS; ERYTHROCYTE TRANSFUSION; FATIGUE; FEMALE; FEVER; GASTROENTERITIS; HEADACHE; HERPES SIMPLEX; HUMAN; INTRAVASCULAR HEMOLYSIS; JAPANESE; KIDNEY FUNCTION; MALE; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PHARYNGITIS; PNEUMONIA; QUALITY OF LIFE; RHINOPHARYNGITIS; SEPSIS; SIDE EFFECT; THROMBOEMBOLISM; UPPER RESPIRATORY TRACT INFECTION; VIRAL GASTROENTERITIS;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; COMPLEMENT C5; FEMALE; HEMOGLOBINURIA, PAROXYSMAL; HUMANS; IMMUNOLOGIC FACTORS; JAPAN; MALE; MIDDLE AGED; RISK FACTORS; TREATMENT OUTCOME;

EID: 84886803820     PISSN: 09255710     EISSN: 18653774     Source Type: Journal    
DOI: 10.1007/s12185-013-1404-y     Document Type: Article

References (50)

1. Hillmen P, Lewis SM, Bessler M, Luzzatto L, Dacie JV. Natural history of paroxysmal nocturnal hemoglobinuria. N Engl J Med. 1995;33319:1253-8.
2. Socié G, Mary JY, de Gramont A, Rio B, Leporrier M, Rose C, et al. Paroxysmal nocturnal haemoglobinuria: long-term follow-up and prognostic factors. French Society of Haematology. Lancet. 1996;3489027:573-7.
3. Parker C, Omine M, Richards S, Nishimura J, Bessler M, Ware R, et al. Diagnosis and management of paroxysmal nocturnal hemoglobinuria. Blood. 2005;10612:3699-709.
4. Kelly RJ, Hill A, Arnold LM, Brooksbank GL, Richards SJ, Cullen M, et al. Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival. Blood. 2011;11725:6786-92.
5. Takeda J, Miyata T, Kawagoe K, Iida Y, Endo Y, Fujita T, et al. Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria. Cell. 1993;734:703-11.
6. Yamada N, Miyata T, Maeda K, Kitani T, Takeda J, Kinoshita T. Somatic mutations of the PIG-A gene found in Japanese patients with paroxysmal nocturnal hemoglobinuria. Blood. 1995;854:885-92.
7. Bessler M, Mason PJ, Hillmen P, Miyata T, Yamada N, Takeda J, et al. Paroxysmal nocturnal haemoglobinuria (PNH) is caused by somatic mutations in the PIG-A gene. EMBO J. 1994;131:110-7.
8. Audebert HJ, Planck J, Eisenburg M, Schrezenmeier H, Haberl RL. Cerebral ischemic infarction in paroxysmal nocturnal hemoglobinuria report of 2 cases and updated review of 7 previously published patients. J Neurol. 2005;25211:1379-86.
9. Helley D, de Latour RP, Porcher R, Rodrigues CA, Galy-Fauroux I, Matheron J, et al. Evaluation of hemostasis and endothelial function in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab. Haematologica. 2010;954:574-81.
10. Lewis SM, Dacie JV. The aplastic anaemia-paroxysmal nocturnal haemoglobinuria syndrome. Br J Haematol. 1967;132:236-51.
11. Griscelli-Bennaceur A, Gluckman E, Scrobohaci ML, Jonveaux P, Vu T, Bazarbachi A, et al. Aplastic anemia and paroxysmal nocturnal hemoglobinuria: search for a pathogenetic link. Blood. 1995;855:1354-63.
12. Mortazavi Y, Merk B, McIntosh J, Marsh JC, Schrezenmeier H, Rutherford TR. The spectrum of PIG-A gene mutations in aplastic anemia/paroxysmal nocturnal hemoglobinuria (AA/PNH): a high incidence of multiple mutations and evidence of a mutational hot spot. Blood. 2003;1017:2833-41.
13. Galili N, Ravandi F, Palmero G, Bubis J, Illingworth A, Castro-Malaspina H, et al. Prevalence of paroxysmal nocturnal hemoglobinuria (PNH) cells in patients with myelodysplastic syndromes (MDS), aplastic anemia (AA), or other bone marrow failure (BMF) syndromes: Interim results from the EXPLORE trial. J Clin Oncol. 2009;27(Suppl 15):7082.
14. McKeage K. Eculizumab: a review of its use in paroxysmal nocturnal haemoglobinuria. Drugs. 2011;7117:2327-45.
15. Drey N, Roderick P, Mullee M, Rogerson M. A population-based study of the incidence and outcomes of diagnosed chronic kidney disease. Am J Kidney Dis. 2003;424:677-84.
16. Hillmen P, Elebute M, Kelly R, Urbano-Ispizua A, Hill A, Rother RP, et al. Long-term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria. Am J Hematol. 2010;858:553-9.
17. Rother RP, Bell L, Hillmen P, Gladwin MT. The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease. JAMA. 2005;29313:1653-62.
18. Qian Q, Nath KA, Wu Y, Daoud TM, Sethi S. Hemolysis and acute kidney failure. Am J Kidney Dis. 2010;564:780-4.
19. Nishimura J, Kanakura Y, Ware RE, Shichishima T, Nakakuma H, Ninomiya H, et al. Clinical course and flow cytometric analysis of paroxysmal nocturnal hemoglobinuria in the United States and Japan. Medicine (Baltimore). 2004;833:193-207.
20. Hill A, Richards SJ, Hillmen P. Recent developments in the understanding and management of paroxysmal nocturnal haemoglobinuria. Br J Haematol. 2007;1373:181-92.
21. Parker CJ. The pathophysiology of paroxysmal nocturnal hemoglobinuria. Exp Hematol. 2007;354:523-33.
22. Hillmen P, Muus P, Dührsen U, Risitano AM, Schubert J, Luzzatto L, et al. Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood. 2007;11012:4123-8.
23. Kim JS, Lee JW, Yoon SS, Lee JH, Jo DY, Jang JH, et al. Association between elevated hemolysis at diagnosis and early mortality and risk of thrombosis in paroxysmal nocturnal hemoglobinuria (PNH) patients with cytopenia. Blood. 2010;11621:4241.
24. Kim JS, Jang JH, Lee JW, Yoon SS, Lee JH, Kim YK, et al. Renal impairment ia a risk factor for early mortality in patients with paroxysmal nocturnal haemoglobinuria (PNH). Haematologica. 2011;96(Suppl 2):112.
25. Hill A, Rother RP, Wang X, Morris SM Jr, Quinn-Senger K, Kelly R, et al. Effect of eculizumab on haemolysis-associated nitric oxide depletion, dyspnoea, and measures of pulmonary hypertension in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol. 2010;1493:414-25.
26. Lee J, Jun Ho J, Sung Soo Y, Jin Seok K, Yeo Kyung K, Deog Yeon C, et al. High prevalence and mortality associated with thromboembolism in Asian patients with paroxysmal nocturnal hemglobinuria (PNH). Haematologica. 2010;95(Suppl 2):205-6.
27. Rother RP, Rollins SA, Mojcik CF, Brodsky RA, Bell L. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat Biotechnol. 2007;2511:1256-64.
28. Hillmen P, Hall C, Marsh JC, Elebute M, Bombara MP, Petro BE, et al. Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2004;3506:552-9.
29. Brodsky RA, Young NS, Antonioli E, Risitano AM, Schrezenmeier H, Schubert J, et al. Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Blood. 2008;1114:1840-7.
30. Kanakura Y, Ohyashiki K, Shichishima T, Okamoto S, Ando K, Ninomiya H, et al. Safety and efficacy of the terminal complement inhibitor eculizumab in Japanese patients with paroxysmal nocturnal hemoglobinuria: the AEGIS clinical trial. Int J Hematol. 2011;931:36-46.
31. Webster K, Cella D, Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System: properties, applications, and interpretation. Health Qual Life Outcomes. 2003;1:79.
32. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;392(Suppl 1):S1-266.
33. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;855:365-76.
34. Cella D, Lai JS, Chang CH, Peterman A, Slavin M. Fatigue in cancer patients compared with fatigue in the general United States population. Cancer. 2002;942:528-38.
35. Cocks K, King MT, Velikova G, Fayers PM, Brown JM. Quality, interpretation and presentation of European Organisation for Research and Treatment of Cancer quality of life questionnaire core 30 data in randomised controlled trials. Eur J Cancer. 2008;4413:1793-8.
36. Risitano AM, Notaro R, Marando L, Serio B, Ranaldi D, Seneca E, et al. Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab. Blood. 2009;113:4094-100.
37. Hillmen P, Young NS, Schubert J, Brodsky RA, Socié G, Muus P, et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2006;35512:1233-43.
38. Kim JS, Jang JH, Lee JW, Yoon SS, Lee JH, Kim YK, et al. Renal impairment is a risk factor for early mortality in patients with paroxysmal nocturnal hemoglobinuria (PNH). 2011. Presented at the 16th Congress of the European Hematology Association (EHA); June 9-12, 2011; London, UK.
39. Pottier P, Fouassier M, Hardouin JB, Volteau C, Planchon B. D-dimers, thrombin-antithrombin complexes, and risk factors for thromboembolism in hospitalized patient. Clin Appl Thromb Hemost. 2009;156:666-75.
40. Hall C, Richards S, Hillmen P. Primary prophylaxis with warfarin prevents thrombosis in paroxysmal nocturnal hemoglobinuria (PNH). Blood. 2003;10210:3587-91.
41. Cheng KL, Brody J, Warshall CE, Sloand EM, Allen SL. Paroxysmal nocturnal hemoglobinuria following alemtuzumab immunosuppressive therapy for myelodysplastic syndrome and complicated by recurrent life-threatening thrombosis despite anticoagulation: successful intervention with eculizumab and fondaparinux. Leuk Res. 2010;344:e85-7.
42. Moyo VM, Mukhina GL, Garrett ES, Brodsky RA. Natural history of paroxysmal nocturnal haemoglobinuria using modern diagnostic assays. Br J Haematol. 2004;1261:133-8.
43. de Latour RP, Mary JY, Salanoubat C, Terriou L, Etienne G, Mohty M, et al. Paroxysmal nocturnal hemoglobinuria: natural history of disease subcategories. Blood. 2008;1128:3099-106.
44. Palareti G, Leali N, Coccheri S, Poggi M, Manotti C, D'Angelo A, et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. Lancet. 1996;3489025:423-8.
45. Hill A, Sapsford RJ, Scally A, Kelly R, Richards SJ, Khurisgara G, et al. Under-recognized complications in patients with paroxysmal nocturnal haemoglobinuria: raised pulmonary pressure and reduced right ventricular function. Br J Haematol. 2012;1583:409-14.
46. Weitz IC, Razavi P, Rochanda L, Zwicker J, Furie B, Manly D, et al. Eculizumab therapy results in rapid and sustained decreases in markers of thrombin generation and inflammation in patients with PNH independent of its effects on hemolysis and microparticle formation. Thromb Res. 2012;1303:361-8.
47. Nath KA, Vercellotti GM, Grande JP, Miyoshi H, Paya CV, Manivel JC, et al. Heme protein-induced chronic renal inflammation: suppressive effect of induced heme oxygenase-1. Kidney Int. 2001;591:106-17.
48. Jang JH, Lee JW, Kim JS, Yoon SS, Lee JH, Kim YK, et al. Poor clinical outcomes in non transfused patients with paroxysmal nocturnal hemoglobinuria (PNH). Haematologica. 2011;96(Suppl 2):595.
49. Sugimori C, Chuhjo T, Feng X, Yamazaki H, Takami A, Teramura M, et al. Minor population of CD55-CD59-blood cells predicts response to immunosuppressive therapy and prognosis in patients with aplastic anemia. Blood. 2006;1074:1308-14.
50. Brodsky RA. Advances in the diagnosis and therapy of paroxysmal nocturnal hemoglobinuria. Blood Rev. 2008;222:65-74.